<DOC>
	<DOCNO>NCT00995358</DOCNO>
	<brief_summary>The purpose study evaluate overall survival immunological monitoring peptide vaccination therapy use novel cancer testis antigens locally advanced , recurrent , metastatic esophageal squamous cell carcinoma ( ESCC ) .</brief_summary>
	<brief_title>A Study With Peptide Vaccination Treating Patients With Esophageal Cancer</brief_title>
	<detailed_description>The phase I vaccination study use peptide derive TTK , LY6K , IMP-3 locally advance , recurrent metastatic esophageal squamous cell carcinoma ( ESCC ) fail standard therapy indicate vaccine treatment well tolerate feasible , antigen-specific T cell response strongly induce vaccination objective clinical response . Thus , currently initiate randomize phase II clinical vaccination study cohort ESCC evaluate survival benefit cancer vaccination .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS Locally advance , recurrent metastatic esophageal squamous cell carcinoma fail standard therapy PATIENTS CHARACTERISTICS ECOG performance status 02 Age≧ 20≦ 80years WBC≥ 2,000/mm³ Platelet count ≥ 75,000/mm³ Total bilirubin ≤ 2.0 x institutional normal upper limit AST , ALT , ALP ≤ 2.5 x institutional normal upper limit Creatinine ≤ 1.5 x institutional normal upper limit No therapy 4 week prior initiation trial Able willing give valid write informed consent Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) Breastfeeding Serious bleed disorder Serious infection require antibiotic Concomitant treatment steroid immunosuppressing agent Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Epitope peptide</keyword>
	<keyword>CTL</keyword>
	<keyword>Esophageal cancer</keyword>
	<keyword>Vaccination</keyword>
</DOC>